News Jasper Therapeutics, Inc.

Equities

JSPR

US4718712023

Market Closed - Nasdaq Other stock markets 01:30:00 08/05/2024 am IST			5-day change	1st Jan Change
22.77 ^USD	+1.47%		-4.61%	+188.59%

07/05	Certain Restricted Stock Units of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	CI
07/05	Certain Stock Options of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jasper Therapeutics to Present at Upcoming Investor Conferences in May	08/05	AQ
Certain Restricted Stock Units of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	07/05	CI
Certain Stock Options of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	07/05	CI
Certain Common Stock of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	07/05	CI
HC Wainwright Starts Jasper Therapeutics With Buy Rating, $65 Price Target	06/05	MT
Jasper Therapeutics : Corporate Presentation April 2024	16/04	PU
Evercore ISI Initiates Jasper Therapeutics With Outperform Rating, Price Target is $65	03/04	MT
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference	03/04	AQ
Jasper Therapeutics Initiated at Outperform, Speculative Risk by RBC, Price Target Set at $70 Amid Bullish View on Lead Asset	28/03	MT
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	22/03	AQ
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria	19/03	AQ
Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria	19/03	CI
TD Cowen Initiates Jasper Therapeutics With Outperform Rating	18/03	MT
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia	15/03	AQ
Jasper Therapeutics, Inc. Announces Additional Positive Phase 1b/2a Data on Briquilimab as A Conditioning Agent in the Treatment of Fanconi Anemia	15/03	CI
Jasper Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04/03	CI
Jasper Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	04/03	CI
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments	04/03	AQ
Jasper Therapeutics : Corporate Presentation March 2024	04/03	PU
Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference	27/02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Jasper Therapeutics, Inc.

Equities

JSPR

US4718712023

Summary

Filters